1. France Stocks

  2. •

    Basic Materials

  3. •

    Agricultural Inputs
Amoéba S.A.

Amoéba S.A.

ALMIB.PA
Amoéba S.A.undefined flagEuronext Paris
0.75
EUR
-0.02
- -
58.65MMarket Cap
Amoéba S.A.
ALMIB.PA
(Euronext Paris)

Recent

price

0.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
0.02
0.08
0.06
0.03
0.02
0.03
0.02
0.02
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.07
-0.14
-0.26
-0.9
-1
-1.04
-1.2
-0.92
-0.5
-0.44
-0.24
-0.29
-0.13
- -
Basic EPS, GAAP
- -
-0.17
-0.01
-0.55
-1.42
-1.57
-1.01
-0.92
-0.45
-0.2
-0.25
-0.14
-0.26
-0.1
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.05
-0.12
-0.24
-0.87
-0.98
-1.02
-1.18
-0.89
-0.48
-0.42
-0.21
-0.27
-0.11
- -
Book Value per Share
- -
0.02
-0.24
0.16
1.7
2.7
1.55
0.32
0.22
-0.03
-0.13
0.17
-0.08
-0.21
- -
Tangible Book Value per Share
- -
4
4
4
4
6
6
6
8
16
18
34
49
50
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
-263.21
-161.58
-414.82
-2,829.38
-4,567.86
-3,684.35
-4,456.77
-4,495.13
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
1
1
2
1
1
1
1
1
1
Depreciation Expense
- -
- -
-1
-1
-4
-6
-6
-7
-7
-8
-8
-8
-14
-7
-8
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-302.9
-172.43
-438.07
-2,851.44
-4,579.52
-3,865.79
-5,907.09
-5,919.1
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-1
2
8
12
10
3
-3
4
-5
3
-4
-3
- -
Working Capital
- -
1
1
1
1
2
6
7
- -
8
- -
- -
3
10
9
LT Debt
1
1
- -
3
11
19
13
5
4
2
- -
8
-4
-10
-5
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
351.7%
720.87%
-48.5%
Free Cash Flow
14.81%
37.94%
45.43%
Net Income, GAAP
12.91%
9.75%
25.96%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.29
2024
- -
- -
- -
- -
-0.13
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Kemistar Corporation Limited (KEMISTAR.BO)
Pure Harvest Corporate Group, Inc. (PHCG)
Integrated Cannabis Solutions, Inc. (IGPK)
Hindustan Motors Limited (HINDUST.BO)
KSE Limited (KSE.NS)
Biotalys N.V. (BTLS.BR)
Business
Amoéba S.A. (ALMIB.PA) develops and markets biological biocides based on Willaertia magna C2c Maky amoeba to control microbial contamination in industry and the environment. The company offers its flagship product Willaertia magna C2c Maky, a naturally occurring predatory amoeba that feeds on pathogenic bacteria such as Legionella pneumophila; liquid biocidal formulations under the brand AMX for applications including water systems, cooling towers, and process waters; and complementary services encompassing on-site testing, implementation support, and customized treatment programs. Amoéba targets industrial sectors vulnerable to biofouling and waterborne pathogens, including cooling systems in power plants, manufacturing facilities, data centers, and hospitals; its primary markets encompass Europe, with expanding operations in North America and Asia. Founded in 2010 and headquartered in Chassieu, near Lyon, France, the company operates as a standalone entity focused on sustainable alternatives to chemical biocides. In recent developments, Amoéba has pursued strategic partnerships, notably collaborating with Veolia on pilot projects for Legionella control in water networks and with Suez for industrial water treatment trials in 2024. The company secured a €3.5 million funding round in late 2024 from existing investors to accelerate AMX commercialization and R&D for agricultural applications. Additionally, Amoéba launched expanded AMX formulations certified for EU biocidal regulations in early 2025 and initiated U.S. market entry via regulatory filings with the EPA. These initiatives reflect a shift toward global scaling and diversified revenue streams beyond initial Legionella-focused sales.